Thrombosis risks of permanent vascular access

Aim. To identify the factors affecting the occurrence of thrombosis of permanent vascular access and to determine their significance. Materials and Methods. The results of treatment of 168 patients with native arteriovenous radio-cephalic fistula were analyzed. The results of treatment were traced within 1 year. According to the results of treatment, patients were divided into 2 groups: the 1st group – patients who did not develop thrombosis of the arteriovenous fistula within 1 year of hemodialysis, and the 2nd group – patients with a dysfunction of permanent vascular access developed due to thrombosis within the first year. Results. On the basis of the obtained data, the risk factors for thrombosis of permanent vascular access within 6 months were: repeated operations, duration of anticoagulant therapy, correction of anticoagulant therapy, antibiotic therapy. Risk factors for thrombosis of the PVA for the period from 6 months to 12 months were: atherosclerosis, fistula vein diameter, repeated operations, the number of repeated operations, a reason for a repeated operation, duration of anticoagulant therapy, correction of anticoagulant therapy, antibiotic therapy. Conclusions. The results of the study suggest that the realization of the identified risk factors is not the only cause of complications. For a more detailed consideration of the probability for thrombosis of permanent vascular access in different time intervals, it seems appropriate to use multidimensional mathematical modeling.

[1]  A. Egorov,et al.  [Effect of genetic polymorphisms on functioning of a permanent vascular access in patients on dialysis]. , 2019, Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery.

[2]  J. Golledge,et al.  A Systematic Review and Meta-Analysis of Circulating Biomarkers Associated with Failure of Arteriovenous Fistulae for Haemodialysis , 2016, PloS one.

[3]  C. Yeh,et al.  Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy. , 2016, Current vascular pharmacology.

[4]  I. Chetter,et al.  The Impact of Vein Mechanical Compliance on Arteriovenous Fistula Outcomes. , 2016, Annals of vascular surgery.

[5]  N. Fekih-Mrissa,et al.  Association Between Thrombophilic Gene Mutations and the Risk of Vascular Access Thrombosis in Hemodialysis Patients , 2016, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  A. Da Silva,et al.  Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. , 2015, The Cochrane database of systematic reviews.

[7]  S. Walsh,et al.  Predictive Parameters of Arteriovenous Fistula Functional Maturation in a Population of Patients with End-Stage Renal Disease , 2015, PloS one.

[8]  D. H. King,et al.  Volume Blood Flow, Static Pressure Ratio and Venous Conductance in Native Arterio-venous Fistulae: Three Surveillance Methods Compared , 2015, The journal of vascular access.

[9]  S. Shahidi,et al.  Comparison of vascular access use in hemodialysis patients in Isfahan in 2003 and 2013 , 2015, Indian journal of nephrology.

[10]  Гришин Олег Витальевич,et al.  Психогенная одышка и гипокапния у больных ишемической болезнью сердца до и после коронарного шунтирования Ангиология и сосудистая хирургия , 2012 .

[11]  Ольга Вилоровна Решетько,et al.  Влияние генетических полиморфизмов на эффективность лозартана у больных эссенциальной артериальной гипертензией , 2012 .

[12]  A. Da Silva,et al.  Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. , 2008, The Cochrane database of systematic reviews.

[13]  P. Rutherford,et al.  Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. , 2003, The Cochrane database of systematic reviews.

[14]  William H. Barker,et al.  CLINICAL EPIDEMIOLOGY: THE ESSENTIALS. , 1984 .